Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization - 03/09/21
pages | 10 |
Iconographies | 6 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Lung metastasis of Triple-negative breast cancer (TNBC) causes severe breath-related events and poor prognosis. Ruyiping (RYP), a traditional Chinese medicine prescription, is used to treat breast cancer lung metastasis in clinical practice. This study was to explore the anti-lung-metastatic activities and mechanism of RYP extract by regulating macrophage polarization. The results showed that RYP can inhibit the viability and induce the apoptosis of TNBC cells. In in vitro experiments, RYP significantly inhibited the invasion and migration ability of TNBC cells promoted by M2, the subtype of macrophage which increased TNBC metastasis related genes. In in vivo experiments, RYP reduced the TNBC progression and lung metastasis. M2/M1 ration in the lung and M2 in the tumor was reduced by RYP, as well as M2 master regulator Stat6. Therefore, RYP extract may exhibit anti-lung metastasis function by reducing M2 in both tumor and lung through reducing Stat6.
Le texte complet de cet article est disponible en PDF.Highlights |
• | RYP inhibits proliferation, mobility, invasion and induces apoptosis of TNBC cells. |
• | RYP reduces M2 polarization and M2 promoted metastatic ability and EMT of TNBC cells. |
• | RYP inhibits tumor growth and lung metastasis in TNBC mouse model. |
• | RYP reduces M2 and EMT genes in tumor and lung in TNBC mouse model. |
Abbreviations : RYP, TNBC, EMT, TCM, BLI, real-time PCR, MTT, H&E, OD, DMEM, RPMI1640, CM
Keywords : Triple negative breast cancer, Lung metastasis, Ruyiping extract, Macrophage polarization
Plan
Vol 141
Article 111883- septembre 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?